XERS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
107.2M
+16.4%
92.1M
+10.8%
83.1M
-3.1%
85.8M
+15.4%
74.4M
Cost of Revenue
12.4M
-0.7%
12.5M
+18.3%
10.6M
-3.4%
10.9M
-0.4%
11.0M
Gross Profit
94.8M
+19.1%
79.6M
+9.7%
72.6M
-3.1%
74.9M
+18.1%
63.4M
Operating Expenses
77.9M
+4.7%
74.4M
+15.1%
64.6M
+11.3%
58.1M
+2.5%
56.7M
R&D
11.1M
+3.6%
10.7M
+21.5%
8.8M
+11.5%
7.9M
+5.2%
7.5M
SG&A
64.1M
+5.0%
61.0M
+14.8%
53.1M
+11.9%
47.5M
+2.2%
46.5M
Operating Income
16.9M
+227.1%
5.2M
-34.7%
7.9M
-52.8%
16.8M
+149.2%
6.7M
EBITDA
19.9M
+143.1%
8.2M
-25.1%
11.0M
-44.7%
19.8M
+102.6%
9.8M
Net Income
11.3M
+136.3%
-31101000
-1492.2%
2.2M
-79.8%
11.1M
+1684.4%
621.0K
EPS (Basic)
$0.06
+133.3%
$-0.18
-1900.0%
$0.01
-85.7%
$0.07
$0.00
EPS (Diluted)
$0.06
+133.3%
$-0.18
-1900.0%
$0.01
-83.3%
$0.06
$0.00
Shares (Diluted)
189.9M
+9.9%
172.8M
-2.7%
177.6M
-11.8%
201.4M
+13.4%
177.6M
Xeris Biopharma (XERS) — Financials